inositol has been researched along with Parkinson Disease in 15 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "myo-Inositol was raised by about 15%, again uniformly throughout the brain, but there was no evidence for changed levels of choline." | 2.41 | A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. ( Firbank, MJ; Harrison, RM; O'Brien, JT, 2002) |
| "Although no difference was found between groups with RBD and IPD without dream enactment behavior in demographic characteristics, duration of disease, mean levodopa dosage and duration of levodopa use, all UPDRS scores (total, motor and cognitive) were worse in RBD group (p<0." | 1.33 | Brainstem 1H-MR spectroscopy in patients with Parkinson's disease with REM sleep behavior disorder and IPD patients without dream enactment behavior. ( Dincer, A; Hanoglu, L; Meral, H; Ozer, F, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ruz, C | 1 |
| Alcantud, JL | 1 |
| Vives, F | 1 |
| Arrebola, F | 1 |
| Hardy, J | 1 |
| Lewis, PA | 1 |
| Manzoni, C | 1 |
| Duran, R | 1 |
| Cengiz, S | 1 |
| Arslan, DB | 1 |
| Kicik, A | 1 |
| Erdogdu, E | 1 |
| Yildirim, M | 1 |
| Hatay, GH | 1 |
| Tufekcioglu, Z | 1 |
| Uluğ, AM | 1 |
| Bilgic, B | 1 |
| Hanagasi, H | 1 |
| Demiralp, T | 1 |
| Gurvit, H | 1 |
| Ozturk-Isik, E | 1 |
| Ren, X | 1 |
| Hinchie, A | 1 |
| Swomley, A | 1 |
| Powell, DK | 1 |
| Butterfield, DA | 1 |
| Waragai, M | 1 |
| Moriya, M | 1 |
| Nojo, T | 1 |
| Papadopoulos, VE | 1 |
| Nikolopoulou, G | 1 |
| Antoniadou, I | 1 |
| Karachaliou, A | 1 |
| Arianoglou, G | 1 |
| Emmanouilidou, E | 1 |
| Sardi, SP | 1 |
| Stefanis, L | 2 |
| Vekrellis, K | 1 |
| Kuo, CL | 1 |
| Kallemeijn, WW | 1 |
| Lelieveld, LT | 1 |
| Mirzaian, M | 1 |
| Zoutendijk, I | 1 |
| Vardi, A | 1 |
| Futerman, AH | 1 |
| Meijer, AH | 1 |
| Spaink, HP | 1 |
| Overkleeft, HS | 1 |
| Aerts, JMFG | 1 |
| Artola, M | 1 |
| Dermentzaki, G | 1 |
| Dimitriou, E | 1 |
| Xilouri, M | 1 |
| Michelakakis, H | 1 |
| Ginns, EI | 1 |
| Mak, SK | 1 |
| Ko, N | 1 |
| Karlgren, J | 1 |
| Akbarian, S | 1 |
| Chou, VP | 1 |
| Guo, Y | 1 |
| Lim, A | 1 |
| Samuelsson, S | 1 |
| LaMarca, ML | 1 |
| Vazquez-DeRose, J | 1 |
| Manning-Boğ, AB | 1 |
| Adams, BT | 1 |
| Niccoli, S | 1 |
| Chowdhury, MA | 1 |
| Esarik, AN | 1 |
| Lees, SJ | 1 |
| Rempel, BP | 1 |
| Phenix, CP | 1 |
| Almuqbel, M | 1 |
| Melzer, TR | 1 |
| Myall, DJ | 1 |
| MacAskill, MR | 1 |
| Pitcher, TL | 1 |
| Livingston, L | 1 |
| Wood, KL | 1 |
| Keenan, RJ | 1 |
| Dalrymple-Alford, JC | 1 |
| Anderson, TJ | 1 |
| Yap, TL | 1 |
| Gruschus, JM | 1 |
| Velayati, A | 1 |
| Westbroek, W | 1 |
| Goldin, E | 1 |
| Moaven, N | 1 |
| Sidransky, E | 1 |
| Lee, JC | 1 |
| Firbank, MJ | 1 |
| Harrison, RM | 1 |
| O'Brien, JT | 1 |
| Hanoglu, L | 1 |
| Ozer, F | 1 |
| Meral, H | 1 |
| Dincer, A | 1 |
| Prestel, J | 1 |
| Gempel, K | 1 |
| Hauser, TK | 1 |
| Schweitzer, K | 1 |
| Prokisch, H | 1 |
| Ahting, U | 1 |
| Freudenstein, D | 1 |
| Bueltmann, E | 1 |
| Naegele, T | 1 |
| Berg, D | 1 |
| Klopstock, T | 1 |
| Gasser, T | 1 |
| Lucetti, C | 1 |
| Del Dotto, P | 1 |
| Gambaccini, G | 1 |
| Bernardini, S | 1 |
| Bianchi, MC | 1 |
| Tosetti, M | 1 |
| Bonuccelli, U | 1 |
1 review available for inositol and Parkinson Disease
| Article | Year |
|---|---|
A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease.
Topics: Alzheimer Disease; Aspartic Acid; Brain; Choline; Humans; Inositol; Magnetic Resonance Spectroscopy; | 2002 |
14 other studies available for inositol and Parkinson Disease
| Article | Year |
|---|---|
Seventy-Two-Hour LRRK2 Kinase Activity Inhibition Increases Lysosomal GBA Expression in H4, a Human Neuroglioma Cell Line.
Topics: Cell Line; Cell Line, Tumor; Enzyme Inhibitors; Glioma; Glucosylceramidase; Humans; Inositol; Leucin | 2022 |
Identification of metabolic correlates of mild cognitive impairment in Parkinson's disease using magnetic resonance spectroscopic imaging and machine learning.
Topics: Cognitive Dysfunction; Creatine; Humans; Inositol; Machine Learning; Magnetic Resonance Imaging; Mag | 2022 |
Profiles of brain oxidative damage, ventricular alterations, and neurochemical metabolites in the striatum of PINK1 knockout rats as functions of age and gender: Relevance to Parkinson disease.
Topics: Animals; Aspartic Acid; Biomarkers; Brain; Corpus Striatum; Disease Models, Animal; Female; Gene Kno | 2019 |
Decreased N-Acetyl Aspartate/Myo-Inositol Ratio in the Posterior Cingulate Cortex Shown by Magnetic Resonance Spectroscopy May Be One of the Risk Markers of Preclinical Alzheimer's Disease: A 7-Year Follow-Up Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Biomarkers; Cognitive Dysfunction; Diseas | 2017 |
Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Brain; Disease Models, Animal; Exosomes; Glucosylceramidase; Humans; Inosi | 2018 |
In vivo inactivation of glycosidases by conduritol B epoxide and cyclophellitol as revealed by activity-based protein profiling.
Topics: Animals; beta-Glucosidase; Brain; Cyclohexanols; Disease Models, Animal; Enzyme Assays; Glucosylcera | 2019 |
Loss of β-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells.
Topics: alpha-Synuclein; Animals; Autophagy; Cell Differentiation; Cell Line; Gaucher Disease; Glucosylceram | 2013 |
Neuroinflammation and α-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction.
Topics: alpha-Synuclein; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Evoked Potentials, Moto | 2014 |
N-Alkylated aziridines are easily-prepared, potent, specific and cell-permeable covalent inhibitors of human β-glucocerebrosidase.
Topics: Alkylation; Aziridines; Enzyme Inhibitors; Gaucher Disease; Glucosylceramidase; HeLa Cells; Humans; | 2015 |
Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Bayes Theorem; Case-Control Studies; Choline; Cognitive Dysf | 2016 |
Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.
Topics: alpha-Synuclein; Amino Acid Substitution; Cell Line, Tumor; Enzyme Inhibitors; Gaucher Disease; Gluc | 2011 |
Brainstem 1H-MR spectroscopy in patients with Parkinson's disease with REM sleep behavior disorder and IPD patients without dream enactment behavior.
Topics: Aged; Aspartic Acid; Brain Stem; Case-Control Studies; Choline; Creatine; Female; Humans; Inositol; | 2006 |
Clinical and molecular characterisation of a Parkinson family with a novel PINK1 mutation.
Topics: Adult; Aged; Basal Ganglia; Biomarkers; Cell Line; DNA Mutational Analysis; Energy Metabolism; Femal | 2008 |
Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson's disease patients.
Topics: Aged; Aspartic Acid; Basal Ganglia; Brain Chemistry; Choline; Creatine; Female; Humans; Inositol; Ma | 2001 |